SEC Form 4 · accession 0001144204-18-055025
Aclaris Therapeutics, Inc. · ACRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anand Mehra
Director
Period of report
Oct 22, 2018
Accepted (ET)
Oct 23, 2018 · 7:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001557746
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 22, 2018 | P | 372,093 | $10.75 | A | 1,911,573 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Such shares of the Company's Common Stock are owned by Sofinnova Venture Partners VIII, L.P. ("Sofinnova VIII"). The Reporting Person is a managing member of Sofinnova Management VIII, L.L.C., the general partner of Sofinnova VIII, and as such may be deemed to have shared voting and dispositive power over such shares with James I. Healy and Michael F. Powell, the other managing members of Sofinnova Management VIII, L.L.C. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein.